Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Interaction Between a Natural Aldehyde Dehydrogenase 2 (ALDH2) Inhibitor and Alcohol (COCADEP/2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02309801
Recruitment Status : Completed
First Posted : December 5, 2014
Last Update Posted : December 5, 2014
Sponsor:
Collaborator:
Ministerio de Sanidad, Servicios Sociales e Igualdad
Information provided by (Responsible Party):
Parc de Salut Mar

Brief Summary:
The main objective is to assess whether a natural inhibitor of aldehyde dehydrogenase 2 (ALDH2) contained in a soy extract could interfere on alcohol metabolism and effects in humans.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: Daidzin Dietary Supplement: Alcohol Phase 1

Detailed Description:

Soybeans contain isoflavones, which are biologically active polyphenols known as antioxidants and phytoestrogens. These isoflavones include daidzin, daidzein, genistin and glycitin, and have been implicated in the beneficial effects of soy consumption.

Daidzin and daidzein are isoflavones contained in soybean that can act as natural inhibitors of aldehyde dehydrogenase 2. Animal studies have demonstrated that some soy isoflavones can reduce the auto-administration of cocaine and suggest they might be useful to treat cocaine dependence.

Aldehyde dehydrogenase inhibitors, as disulfiram, are currently used in humans to treat alcohol dependence because they interfere with ethanol metabolism (specifically in the transformation of acetaldehyde to acetate.

Alcohol intake after disulfiram administration increases concentration of acetaldehyde in the blood (five to 10 times higher than that found during metabolism of the same amount of alcohol alone). The combination produced acute symptoms of a severe "hangover" (named disulfiram-like reaction), and the patient may experience symptoms as flushing of the skin, tachycardia, shortness of breath, nausea, vomiting, throbbing headache, visual disturbances, mental confusion, and in some cases severe reactions as postural syncope, and circulatory collapse.

In addition, disulfiram have demonstrated clinical efficacy in cocaine dependence. The mechanism of action for that effects are related to its ability to decrease dopamine degradation by inhibiting the dopamine-beta-hydroxylase enzyme (metabolizes dopamine to norepinephrine), and increasing its concentrations in some areas of the brain.

The aim of the study is to assess whether a soy extract containing isoflavones (daidzin, daidzein and genistein) could interfere on alcohol metabolism and produce adverse effects in humans.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Human Pharmacology Study to Evaluate the Interaction Between a Natural Inhibitor of Aldehyde Dehydrogenase 2 (ALDH2) and Alcohol in Healthy Volunteers. Pilot Clinical Trial
Study Start Date : July 2012
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2014

Arm Intervention/treatment
Experimental: Daidzin and alcohol

Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).

Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.

Dietary Supplement: Daidzin
Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).

Dietary Supplement: Alcohol
Alcohol single oral dose

Active Comparator: Alcohol
Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
Dietary Supplement: Alcohol
Alcohol single oral dose




Primary Outcome Measures :
  1. Area Under the Concentration-Time curve (AUC 2-10h) [ Time Frame: From 2h to 10h after the first administration ]
    Calculation of AUC for blood alcohol concentrations


Secondary Outcome Measures :
  1. Change in signs and symptoms of disulfiram-like reaction [ Time Frame: From baseline to 10h after the first administration ]
    Vital signs (heart rate, blood pressure, respiration rate, oral and facial temperature) and adverse effects measured by visual analogue scales (nausea, vomiting, vertigo, dizziness, headache, breathing difficulty, facial flushing)

  2. Change in drunkenness and euphoria effects [ Time Frame: From baseline to 10h after the first administration ]
    Drunkenness and euphoria will be measured by a visual analogue scale (VAS).

  3. Area Under the Concentration-Time curve (AUC 0-10h) [ Time Frame: From baseline to 24h after the first administration ]
    Calculation of AUC of plasmatic concentrations of daidzein, genistein and equol

  4. Number of participants with Serious and non-serious adverse events [ Time Frame: 3 days after each condition ]
    Collection of adverse events spontaneously reported by the participants and/or observed by the investigators.

  5. Change in other subjective effects [ Time Frame: From baseline to 10h after the first administration ]
    Subjective effects will be measured with the Addiction Research Center Inventory (ARCI)

  6. Elimination half-life [ Time Frame: From 2h to 10h after the first administration ]
    Calculation of elimination half-life from blood ethanol concentrations

  7. Elimination half-life [ Time Frame: From baseline to 24h after the first administration ]
    Calculation of elimination half-life of plasmatic concentrations of daidzein, genistein and equol

  8. Cumulative amount of drug excreted into urine up to collection time [ Time Frame: From baseline to 24h after the first administration ]
    Urine will be collected in the following periods:0-2h,2-8h,8-14h,14-24 h after administration. Concentrations of daidzein, genistein and equol will be measured



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Understanding and accepting the study procedures and signing the informed consent
  • Clinical history and physical examination demonstrating no organic or psychiatric disorders
  • The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically
  • The body mass index (BMI=weigh/height2) will range from 19 to 27 kg/m2, and the weight from 50 to 100 kg
  • Ethanol consumption of minimum 2 units per week and previous experience with ethanol intoxication
  • Women with regular menstrual cycle (26-32 days)

Exclusion Criteria:

  • Not meeting the inclusion criteria
  • History or clinical evidence of alcoholism, psychiatric disorders, drug abuse or dependence, or regular use of psychoactive drugs
  • Having suffered any organic disease or major surgery in the three months prior to the study start
  • Smokers
  • Consumption of more than five coffees, teas, colas, other stimulant or xanthine beverages daily in the three months prior to the beginning of the study
  • Taking more than 20 g of alcohol per day in women and 40 g of alcohol per day in men
  • Regular use of any drug in the month prior to the study sessions.The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session
  • Blood donation 8 weeks before or participation in other clinical trials with drugs in the previous 12 weeks
  • Subjects with allergy, intolerance or adverse reactions to alcohol, soya and lactose.
  • History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs
  • Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed
  • Subjects with positive serology to Hepatitis B, C or HIV
  • Pregnant or breastfeeding women. Women not using effective contraceptive methods
  • History or presence of breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02309801


Locations
Layout table for location information
Spain
Parc de Salut Mar.
Barcelona, Spain, 08003
Sponsors and Collaborators
Parc de Salut Mar
Ministerio de Sanidad, Servicios Sociales e Igualdad
Investigators
Layout table for investigator information
Principal Investigator: Magí Farré, MD, PhD Parc de Salut Mar
Layout table for additonal information
Responsible Party: Parc de Salut Mar
ClinicalTrials.gov Identifier: NCT02309801    
Other Study ID Numbers: PSMAR/IMIM/COCADEP/2
First Posted: December 5, 2014    Key Record Dates
Last Update Posted: December 5, 2014
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Daidzin
Alcohol Deterrents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action